Recent 8-K filings for EXEL
Highest-materiality recent filing
Exelixis wins patent case against MSN; generic launch blocked until Jan 2030
- Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.
- Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.
-
Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback
Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.
-
Exelixis Q4 revenue $599M, diluted EPS $0.88; cabozantinib franchise up 17% in FY2025
Q4 2025 total revenue $598.7M vs $566.8M YoY; GAAP diluted EPS $0.88 vs $0.48.
-
Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026
Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).
-
Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO
Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.
-
Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303
Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).
-
Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M
Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).
-
Exelixis approves special PSU awards for all employees with $60 stock price performance goal
CEO Michael Morrissey receives 589,719 shares of PSU; other NEOs receive between 132,819 and 170,009 shares.
-
Exelixis board authorizes additional $500M stock repurchase program
New $500M authorization to be completed by Dec 31, 2025; current $500M program expected to finish in Q2 2025.
-
Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76
Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.
-
Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance
Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.
-
Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC
Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.
-
Exelixis wins patent case against MSN; generic launch blocked until Jan 2030
Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.
-
Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA
Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.
-
Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031
Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).
-
Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths
Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.75 · Most common event earnings